| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.08 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.075 | 0.08 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.075 | 0.08 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.11 | 0.08 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.069 | 0.08 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.08 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.074 | 0.08 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.09 | 0.08 |